UBS sets USD 184.00 target for Protagonist Therapeutics stock

Published on 10/14/2026 at 04:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UBS initiated coverage with a Buy rating on October 12, 2026. USD 213.47 million revenue matters for Protagonist Therapeutics stock.

Analyst signals and operating figures

UBS began coverage with a USD 184.00 target on October 12, 2026.
Second-quarter revenue reached USD 213.47 million and diluted earnings per share were USD 2.29.
MarketBeat listed 17 Buy ratings and one Hold rating with a USD 154.44 average target on October 12, 2026.

PTGX, US74366E1029, Illustration mit AI erstellt.

UBS initiated coverage of Protagonist Therapeutics, Inc. with a Buy rating and a USD 184.00 price target on October 12, 2026, giving Protagonist Therapeutics stock a fresh analyst benchmark. Investing.com reported that UBS sees PN-881 as a key pipeline value driver and expects its 2027 and 2028 estimates to stand 89 percent and 27 percent above consensus.

Three dated valuation signals

The latest move followed an August 5, 2026 quarterly report that showed USD 213.47 million revenue and diluted earnings per share of USD 2.29, versus consensus of USD 212.03 million and USD 2.27, respectively. MarketBeat said quarterly revenue rose 3,746.80 percent year over year.

On August 10, 2026, Goldman Sachs raised its target from USD 110.00 to USD 186.00 and moved its rating from Neutral to Buy, according to MarketBeat.

What does the valuation depend on?

UBS linked its view to commercial potential for PN-881 and to possible royalty revisions for Mimrylo. The firm estimated that its 2027 and 2028 expectations could sit 89 percent and 27 percent above consensus, respectively, while also pointing to PN-477 and PN-8047 as pipeline options with Phase 1 data expected in 2027, as Investing.com reported on October 12, 2026.

The earnings comparison supplies the operating counterweight to the valuation story. Second-quarter net income attributable to common shareholders was USD 162.85 million, while operating cash flow reached USD 219.05 million for the same period, according to the current financial statements for the second quarter of 2026.

MarketBeat's October 12, 2026 overview counted 17 Buy ratings and one Hold rating, with an average target of USD 154.44. That figure sits below the new UBS target, showing how the latest analyst action raises the upper end of the published valuation range rather than resetting the full consensus.

Nasdaq listing and company profile

Protagonist Therapeutics is listed on Nasdaq under ticker PTGX and develops peptide-based medicines for immune-mediated and hematologic diseases. Its second-quarter revenue of USD 213.47 million compares with USD 56.37 million in the first quarter of 2026, while net income increased from USD 3.78 million to USD 162.85 million between those periods.

Analyst targets shape the setup

The current case combines a USD 184.00 UBS target, the USD 190.00 Leerink target reported on October 12, 2026, and a USD 154.44 average target cited by MarketBeat. The spread makes the analyst range itself a material part of the stock story, while the second-quarter figures provide a dated operating anchor.

Market context: Market report S&P 500.